Biochemically Recurrent Prostate Carcinoma Clinical Trial
Official title:
A Phase I Study of 68GA-PSMA-11 PET Imaging for Biochemically Recurrent Prostate Cancer
This phase I trial studies the side effects of 68GA-PSMA-11 PET imaging in patients with prostate cancer that has come back (recurrent). Gallium (68Ga) is a radiotracer that binds to a molecule, PSMA, that is found in abundance on most prostate cancer cells. PSMA is short for 'prostate specific membrane antigen'. Diagnostic procedures, such as 68GA-PSMA-11 PET imaging, may help measure a patient's response to earlier treatment, and may help plan the best treatment for prostate cancer.
PRIMARY OBJECTIVE: I. To provide clinical access to and assess the safety of the investigational agent Gallium Ga 68-labeled prostate specific membrane antigen (PSMA)-11 (68Ga-PSMA-11) positron emission tomography (PET) at City of Hope National Medical Center for patients co-enrolled on Institutional Review Board (IRB) 18517 treatment trial. OUTLINE: Patients receive gallium Ga 68-labeled PSMA-11 intravenously (IV) over less than 1 minute, and then undergo PET over 60 minutes. After completion of study, patients are followed up at 1-3 days, and then at 3 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04423211 -
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
|
Phase 3 | |
| Recruiting |
NCT06105918 -
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
|
Phase 1 | |
| Withdrawn |
NCT04585932 -
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
|
Phase 2 | |
| Recruiting |
NCT04777071 -
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT06229366 -
[Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer
|
Phase 1 | |
| Recruiting |
NCT05054296 -
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
|
Phase 2 | |
| Active, not recruiting |
NCT05320406 -
RElugolix VErsus LeUprolide Cardiac Trial
|
Phase 4 | |
| Terminated |
NCT04928820 -
68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
|
Phase 2 | |
| Terminated |
NCT05437679 -
Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System
|
||
| Recruiting |
NCT06205316 -
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
|
Phase 3 | |
| Recruiting |
NCT04144010 -
Gallium-68 PSMA-11 PET/CT for the Diagnosis of Biochemically Recurrent Prostate Cancer
|
Phase 2 | |
| Completed |
NCT04978675 -
An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT04447703 -
Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study
|
N/A | |
| Completed |
NCT04050215 -
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04336943 -
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
|
Phase 2 |